Last updated on July 2018

Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis


Brief description of study

To demonstrate the clinical efficacy, safety and tolerability of secukinumab compared to placebo in patients with ankylosing spondylitis at Week 16 and long term efficacy and safety up to Week 52.

Clinical Study Identifier: NCT02896127

Contact Investigators or Research Sites near you

Start Over

Novartis Pharmaceuticals

Novartis Investigative Site
Hefei, China

Novartis Pharmaceuticals

Novartis Investigative Site
Beijing, China

Novartis Pharmaceuticals

Novartis Investigative Site
Guangzhou, China

Novartis Pharmaceuticals

Novartis Investigative Site
Wuhan, China

Novartis Pharmaceuticals

Novartis Investigative Site
Changsha, China

Novartis Pharmaceuticals

Novartis Investigative Site
Nanjing, China

Novartis Pharmaceuticals

Novartis Investigative Site
Shanghai, China

Novartis Pharmaceuticals

Novartis Investigative Site
Shanxi Province, China

Novartis Pharmaceuticals

Novartis Investigative Site
Tianjin, China

Novartis Pharmaceuticals

Novartis Investigative Site
Zhejiang, China

Novartis Pharmaceuticals

Novartis Investigative Site
Bruntal, Czechia

Novartis Pharmaceuticals

Novartis Investigative Site
Ostrava, Czechia

Novartis Pharmaceuticals

Novartis Investigative Site
Praha 11, Czechia

Novartis Pharmaceuticals

Novartis Investigative Site
Praha 2, Czechia

Novartis Pharmaceuticals

Novartis Investigative Site
Uherske Hradiste, Czechia

Novartis Pharmaceuticals

Novartis Investigative Site
Busan, Korea, Republic of

Novartis Pharmaceuticals

Novartis Investigative Site
Gwangju, Korea, Republic of

Novartis Pharmaceuticals

Novartis Investigative Site
Incheon, Korea, Republic of

Novartis Pharmaceuticals

Novartis Investigative Site
Seoul, Korea, Republic of

Novartis Pharmaceuticals

Novartis Investigative Site
Reading, United Kingdom

Novartis Pharmaceuticals

Novartis Investigative Site
Bradford, United Kingdom

Novartis Pharmaceuticals

Novartis Investigative Site
Bath, United Kingdom

Novartis Pharmaceuticals

Novartis Investigative Site
Doncaster, United Kingdom

Novartis Pharmaceuticals

Novartis Investigative Site
Hull, United Kingdom

Novartis Pharmaceuticals

Novartis Investigative Site
London, United Kingdom

Novartis Pharmaceuticals

Novartis Investigative Site
Norwich, United Kingdom

Novartis Pharmaceuticals

Novartis Investigative Site
Southampton, United Kingdom

Novartis Pharmaceuticals

Novartis Investigative Site
Wigan, United Kingdom